Drug Patents owned by Astrazeneca

1. List of Bevespi Aerosphere drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9463161 ASTRAZENECA Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
May, 2030

(7 years from now)

US10716753 ASTRAZENECA Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
May, 2030

(7 years from now)

US8324266 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(7 years from now)

US9415009 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(7 years from now)

US8703806 ASTRAZENECA Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents
May, 2030

(7 years from now)

US8808713 ASTRAZENECA Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems
May, 2030

(7 years from now)

US8815258 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents
Mar, 2031

(7 years from now)

Drugs and Companies using FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

BEVESPI AEROSPHERE family patents

26

United States

10

Japan

9

Taiwan, Province of China

8

Lithuania

8

Hungary

7

Russia

7

Korea, Republic of

7

Australia

6

Portugal

6

Spain

6

Croatia

6

Argentina

6

China

6

Hong Kong

6

Slovenia

6

Poland

6

Denmark

6

European Union

5

Cyprus

4

Mexico

3

Brazil

3

San Marino

3

South Africa

3

Canada

3

Ukraine

3

Israel

2

Norway

2

Luxembourg

1

Philippines

1

ME

1

Netherlands

2. List of Brilinta drug patents

BRILINTA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46276 ASTRAZENECA Triazolo(4,5-D)pyrimidine compounds
Oct, 2024

(1 year, 7 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE46276

(Pediatric)

ASTRAZENECA Triazolo(4,5-D)pyrimidine compounds
Apr, 2025

(2 years from now)

US8425934 ASTRAZENECA Pharmaceutical compositions
Apr, 2030

(7 years from now)

US8425934

(Pediatric)

ASTRAZENECA Pharmaceutical compositions
Oct, 2030

(7 years from now)

US10300065 ASTRAZENECA Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
Jan, 2036

(12 years from now)

US10300065

(Pediatric)

ASTRAZENECA Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
Jul, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Nov 5, 2023
M (M) May 9, 2025
Pediatric Exclusivity (PED) Nov 28, 2023

Drugs and Companies using TICAGRELOR ingredient

Market Authorisation Date: 20 July, 2011

Treatment: Reducing the rate of cardiovascular death, myocardial infarction (mi), and stroke in a patient receiving 75-100 mg aspirin daily with a history of mi by administering 60 mg ticagrelor twice daily; Reducing the rate of cardiovascular death, myocardial infarction, and stroke in a patient receiving 75-100 mg aspirin daily and having or who had acute coronary syndrome by administering 60 mg ticagrelor twice daily; Treatment of myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction; Reduction of the rate of cardiovascular death, myocardial infarction, and stroke in patients with a history of myocardial infarction; Treatment of stroke in patients with acute coronary syndrome or a history of myocardial infarction; Treatment of myocardial infarction in patients with acute coronary syndrome or a history of myocardial infarction; Reduction of the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attack; Treatment of myocardial infarction or stroke in patients with coronary artery disease at high risk for such events; Reduction of the rate of a first myocardial infarction or stroke in patients with coronary artery disease at high risk for such events

Dosage: TABLET;ORAL

How can I launch a generic of BRILINTA before it's patent expiration?
More Information on Dosage

BRILINTA family patents

12

United States

5

China

5

Japan

3

Russia

3

Australia

3

European Union

2

Malaysia

2

Brazil

2

New Zealand

2

Canada

1

Portugal

1

Singapore

1

Uruguay

1

Spain

1

Croatia

1

Colombia

1

IB

1

Norway

1

Philippines

1

Mexico

1

Argentina

1

Taiwan, Province of China

1

Sweden

1

Korea, Republic of

1

Hong Kong

1

South Africa

1

Lithuania

1

Cyprus

1

Slovenia

1

Saudi Arabia

1

Hungary

1

Ukraine

1

Israel

1

Poland

1

Chile

1

RS

1

Denmark

3. List of Calquence drug patents

CALQUENCE's oppositions filed in EPO
CALQUENCE Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7459554 ASTRAZENECA Imidazopyrazine tyrosine kinase inhibitors
Nov, 2026

(3 years from now)

US9290504 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(9 years from now)

US11059829 ASTRAZENECA Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate
Jul, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10239883 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors
Jul, 2032

(9 years from now)

US9758524 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(9 years from now)

US10272083 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 31, 2022

Drugs and Companies using ACALABRUTINIB MALEATE ingredient

NCE-1 date: 2021-10-31

Market Authorisation Date: 03 August, 2022

Treatment: Treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with chronic lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with small lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia; Treatment of adult patients with previously untreated small lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with small lymphocytic leukemia

Dosage: TABLET;ORAL

More Information on Dosage

CALQUENCE family patents

32

United States

11

Japan

10

European Union

8

Australia

6

China

6

Israel

5

Spain

5

Korea, Republic of

5

Lithuania

5

Hungary

4

Portugal

4

Croatia

4

IB

4

Taiwan, Province of China

4

Canada

4

Slovenia

4

Poland

4

RS

4

Denmark

3

Singapore

3

Argentina

3

Morocco

3

EA

2

Russia

2

Brazil

2

New Zealand

2

Norway

2

Mexico

2

South Africa

2

Ukraine

2

Chile

1

Turkey

1

Moldova, Republic of

1

Malaysia

1

Guatemala

1

Costa Rica

1

Colombia

1

Dominican Republic

1

Philippines

1

Austria

1

Peru

1

Hong Kong

1

Tunisia

1

India

1

Nicaragua

1

Cyprus

1

ME

1

Ecuador

1

Netherlands

4. List of Calquence drug patents

CALQUENCE's oppositions filed in EPO
CALQUENCE Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7459554 ASTRAZENECA Imidazopyrazine tyrosine kinase inhibitors
Nov, 2026

(3 years from now)

US9290504 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(9 years from now)

US9796721 ASTRAZENECA Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
Jul, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10239883 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors
Jul, 2032

(9 years from now)

US9758524 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(9 years from now)

US10272083 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(11 years from now)

US10167291 ASTRAZENECA Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
Jul, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 21, 2026

Drugs and Companies using ACALABRUTINIB ingredient

Market Authorisation Date: 31 October, 2017

Treatment: Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with small lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated chronic lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily; Treatment of adult patients with chronic lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; Treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with small lymphocytic leukemia; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia; Treatment of adult patients with previously untreated small lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab

Dosage: CAPSULE;ORAL

How can I launch a generic of CALQUENCE before it's patent expiration?
More Information on Dosage

CALQUENCE family patents

32

United States

11

Japan

10

European Union

8

Australia

6

China

6

Israel

5

Spain

5

Korea, Republic of

5

Lithuania

5

Hungary

4

Portugal

4

Croatia

4

IB

4

Taiwan, Province of China

4

Canada

4

Slovenia

4

Poland

4

RS

4

Denmark

3

Singapore

3

Argentina

3

Morocco

3

EA

2

Russia

2

Brazil

2

New Zealand

2

Norway

2

Mexico

2

South Africa

2

Ukraine

2

Chile

1

Turkey

1

Moldova, Republic of

1

Malaysia

1

Guatemala

1

Costa Rica

1

Colombia

1

Dominican Republic

1

Philippines

1

Austria

1

Peru

1

Hong Kong

1

Tunisia

1

India

1

Nicaragua

1

Cyprus

1

ME

1

Ecuador

1

Netherlands

5. List of Daliresp drug patents

DALIRESP's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9468598 ASTRAZENECA Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
Feb, 2023

(a month ago)

US8431154 ASTRAZENECA Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
Feb, 2023

(a month ago)

US8536206 ASTRAZENECA Process for the preparation of roflumilast
Mar, 2024

(11 months from now)

US8604064 ASTRAZENECA Process for the preparation of roflumilast
Mar, 2024

(11 months from now)

US8618142 ASTRAZENECA Process for the preparation of roflumilast
Mar, 2024

(11 months from now)

Drugs and Companies using ROFLUMILAST ingredient

Market Authorisation Date: 28 February, 2011

Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations

Dosage: TABLET;ORAL

How can I launch a generic of DALIRESP before it's patent expiration?
More Information on Dosage

DALIRESP family patents

17

United States

7

European Union

3

Portugal

3

Spain

3

China

3

Korea, Republic of

3

Cyprus

3

Slovenia

3

Denmark

2

Germany

2

Brazil

2

New Zealand

2

Norway

2

Austria

2

Mexico

2

Argentina

2

Taiwan, Province of China

2

Hong Kong

2

EA

2

South Africa

2

Japan

2

Canada

2

ME

2

Yugoslavia

2

Iceland

2

Israel

2

Poland

2

Australia

1

Malaysia

1

Croatia

1

Morocco

1

Peru

1

Tunisia

1

Ukraine

1

Georgia

1

RS

1

Ecuador

6. List of Duaklir Pressair drug patents

DUAKLIR PRESSAIR's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46417 ASTRAZENECA Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
Feb, 2025

(1 year, 10 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6681768 ASTRAZENECA Powder formulation disintegrating system and method for dry powder inhalers
Aug, 2022

(7 months ago)

US8051851 ASTRAZENECA Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler
Apr, 2027

(4 years from now)

US11000517 ASTRAZENECA Dosage and formulation
Mar, 2029

(5 years from now)

US10085974 ASTRAZENECA Dosage and formulation
Mar, 2029

(5 years from now)

Exclusivity Exclusivity Expiration
New Combination (NC) Mar 29, 2022

Drugs and Companies using ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE ingredient

Market Authorisation Date: 29 March, 2019

Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd)

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

DUAKLIR PRESSAIR family patents

8

United States

8

European Union

4

Portugal

4

Russia

4

Spain

4

Korea, Republic of

4

Japan

4

Slovenia

4

Poland

4

Denmark

3

Croatia

3

Mexico

3

Peru

3

China

3

Hungary

3

RS

2

Brazil

2

New Zealand

2

Hong Kong

2

South Africa

2

Lithuania

2

Canada

2

Cyprus

2

Ukraine

2

Israel

2

Australia

2

Ecuador

1

Germany

1

Singapore

1

Malaysia

1

Uruguay

1

Colombia

1

Norway

1

Austria

1

Argentina

1

Taiwan, Province of China

1

ME

1

Chile

7. List of Epanova drug patents

EPANOVA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9050309 ASTRAZENECA DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Jan, 2033

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132112 ASTRAZENECA Type A gelatin capsule containing PUFA in free acid form
Feb, 2025

(1 year, 10 months from now)

US9012501 ASTRAZENECA Type A gelatin capsule containing PUFA in free acid form
Feb, 2025

(1 year, 10 months from now)

US8383678 ASTRAZENECA Type a gelatin capsule containing PUFA in free acid form
Feb, 2025

(1 year, 10 months from now)

US7960370 ASTRAZENECA Type A gelatin capsule containing PUFA in free acid form
Dec, 2026

(3 years from now)

US10117844 ASTRAZENECA DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Jan, 2033

(9 years from now)

US9050308 ASTRAZENECA DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Jan, 2033

(9 years from now)

Drugs and Companies using OMEGA-3-CARBOXYLIC ACIDS ingredient

Market Authorisation Date: 05 May, 2014

Treatment: Treatment of hypertriglyceridemia; Treatment of severe hypertriglyceridemia (500 mg/dl) in adult patients as an adjunct to diet

Dosage: CAPSULE;ORAL

More Information on Dosage

EPANOVA family patents

23

United States

6

Japan

5

China

4

Israel

4

European Union

3

New Zealand

3

Korea, Republic of

2

United Kingdom

2

Portugal

2

Singapore

2

Russia

2

Spain

2

Brazil

2

Philippines

2

Mexico

2

Hong Kong

2

South Africa

2

Canada

2

Cyprus

2

Slovenia

2

Poland

2

Australia

2

Denmark

1

Germany

1

Malaysia

1

Croatia

1

Costa Rica

1

Colombia

1

Dominican Republic

1

Norway

1

Austria

1

Argentina

1

Peru

1

India

1

Lithuania

1

Hungary

1

Ukraine

1

Chile

1

RS

1

Ecuador

8. List of Koselugo drug patents

KOSELUGO's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8178693 ASTRAZENECA N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(9 days ago)

US7425637 ASTRAZENECA N3 alkylated benzimidazole derivatives as MEK inhibitors
Apr, 2024

(1 year, 20 days from now)

US9562017 ASTRAZENECA Hydrogen sulfate salt
Dec, 2026

(3 years from now)

US9156795 ASTRAZENECA Hydrogen sulfate salt
Dec, 2026

(3 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 10, 2025
Orphan Drug Exclusivity (ODE) Apr 10, 2027

Drugs and Companies using SELUMETINIB SULFATE ingredient

NCE-1 date: 2024-04-10

Market Authorisation Date: 10 April, 2020

Treatment: Treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn)

Dosage: CAPSULE;ORAL

More Information on Dosage

KOSELUGO family patents

24

United States

7

Spain

7

China

7

European Union

6

Japan

6

Poland

5

Portugal

5

Brazil

5

Argentina

5

Taiwan, Province of China

5

Korea, Republic of

5

Cyprus

5

Slovenia

5

Iceland

5

Israel

5

Denmark

4

Dominican Republic

4

Hong Kong

4

Australia

3

Singapore

3

Russia

3

Mexico

3

South Africa

3

Canada

3

Hungary

2

New Zealand

2

Lithuania

2

Ukraine

2

Chile

2

Netherlands

1

Germany

1

Malaysia

1

Panama

1

Croatia

1

Norway

1

Austria

1

Belgium

1

Luxembourg

1

RS

1

Ecuador

9. List of Lokelma drug patents

LOKELMA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10413569 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(8 years from now)

US11406662 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(8 years from now)

US8802152 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Apr, 2032

(9 years from now)

US9913860 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(10 years from now)

US10695365 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(10 years from now)

US8877255 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(10 years from now)

US9592253 ASTRAZENECA Extended use zirconium silicate compositions and methods of use thereof
Oct, 2035

(12 years from now)

US10300087 ASTRAZENECA Extended use zirconium silicate compositions and methods of use thereof
Oct, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10335432 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(8 years from now)

US9861658 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(8 years from now)

US9844567 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(8 years from now)

US10398730 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(8 years from now)

US8808750 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 18, 2023
M (M) Apr 24, 2023

Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient

NCE-1 date: 2022-05-18

Market Authorisation Date: 18 May, 2018

Treatment: Treatment of hyperkalemia in adults

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of LOKELMA before it's patent expiration?
More Information on Dosage

LOKELMA family patents

43

United States

8

China

8

Australia

7

Japan

7

European Union

6

Mexico

6

Chile

5

Argentina

5

Korea, Republic of

5

Canada

5

Israel

4

Philippines

4

Taiwan, Province of China

4

South Africa

3

Brazil

3

Hong Kong

2

EA

2

Lithuania

2

Hungary

1

Portugal

1

Turkey

1

Malaysia

1

Spain

1

Croatia

1

Costa Rica

1

Colombia

1

Norway

1

Cyprus

1

Luxembourg

1

Slovenia

1

ME

1

Poland

1

RS

1

Denmark

1

Netherlands

10. List of Lynparza drug patents

LYNPARZA's oppositions filed in EPO
LYNPARZA Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7151102 ASTRAZENECA Phthalazinone derivatives
Apr, 2022

(10 months ago)

US7981889 ASTRAZENECA Phthalazinone derivatives
Oct, 2024

(1 year, 6 months from now)

US7449464 ASTRAZENECA Phthalazinone derivatives
Oct, 2024

(1 year, 6 months from now)

US8247416 ASTRAZENECA Phthalazinone derivative
Sep, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566276 ASTRAZENECA Phthalazinone derivatives
Mar, 2024

(11 months from now)

US8912187 ASTRAZENECA Phthalazinone derivatives
Mar, 2024

(11 months from now)

US9169235 ASTRAZENECA Phthalazinone derivatives
Mar, 2024

(11 months from now)

US8071579 ASTRAZENECA DNA damage repair inhibitors for the treatment of cancer
Aug, 2027

(4 years from now)

US8143241 ASTRAZENECA DNA damage repair inhibitors for treatment of cancer
Aug, 2027

(4 years from now)

US8475842 ASTRAZENECA Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
Dec, 2029

(6 years from now)

US8859562 ASTRAZENECA Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
Aug, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 8, 2027
New Indication (I) Mar 11, 2025

Drugs and Companies using OLAPARIB ingredient

Market Authorisation Date: 17 August, 2017

Treatment: Maintenance treatment of deleterious or suspected deleterious gbrca-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen; Treatment of brca mutated ovarian cancer using parp inhibitor; Treatment of deleterious or suspected deleterious germline or somatic brca-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; Treatment of deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; Treatment of hr-positive, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting, and with endocrine therapy or are inappropriate for endocrine therapy; Maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; Treatment of deleterious or suspected deleterious germline brca-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy; Treatment of hr-negative, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; Maintenance treatment of brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; Maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; Maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; Maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; Maintenance treatment of gbrca- or sbrca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy; Maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; Maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; Maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; Adjuvant treatment of patients with gbrca-mutated human epidermal growth factor receptor 2 (her2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy

Dosage: TABLET;ORAL

How can I launch a generic of LYNPARZA before it's patent expiration?
More Information on Dosage

LYNPARZA family patents

43

United States

16

Japan

15

United Kingdom

11

China

10

European Union

9

Spain

9

Norway

9

Hong Kong

9

Australia

8

Portugal

8

Brazil

8

Korea, Republic of

8

Canada

8

Poland

8

Denmark

7

New Zealand

6

Austria

6

Mexico

6

South Africa

6

Israel

5

Russia

5

Cyprus

4

Taiwan, Province of China

4

Slovenia

4

Hungary

3

Germany

3

Singapore

3

Malaysia

3

Croatia

3

Colombia

3

Argentina

3

EA

3

Lithuania

3

Ukraine

2

Uruguay

2

Peru

2

ME

2

Chile

2

RS

2

Ecuador

1

Costa Rica

1

Dominican Republic

1

Morocco

1

Honduras

1

Tunisia

1

Nicaragua

1

Saudi Arabia

1

Luxembourg

1

Iceland

1

Cuba

11. List of Symbicort drug patents

SYMBICORT's oppositions filed in EPO
SYMBICORT Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7967011

(Pediatric)

ASTRAZENECA Inhalation device
Feb, 2022

(1 year, 1 month ago)

US11311558 ASTRAZENECA Composition for inhalation
Jan, 2023

(a month ago)

US7759328 ASTRAZENECA Composition for inhalation
Jan, 2023

(a month ago)

US8575137 ASTRAZENECA Composition for inhalation
Jan, 2023

(a month ago)

US10166247 ASTRAZENECA Composition for inhalation
Jan, 2023

(a month ago)

US8143239 ASTRAZENECA Composition for inhalation
Jan, 2023

(a month ago)

US10166247

(Pediatric)

ASTRAZENECA Composition for inhalation
Jul, 2023

(4 months from now)

US11311558

(Pediatric)

ASTRAZENECA Composition for inhalation
Jul, 2023

(4 months from now)

US7759328

(Pediatric)

ASTRAZENECA Composition for inhalation
Jul, 2023

(4 months from now)

US8143239

(Pediatric)

ASTRAZENECA Composition for inhalation
Jul, 2023

(4 months from now)

US8575137

(Pediatric)

ASTRAZENECA Composition for inhalation
Jul, 2023

(4 months from now)

US8875699 ASTRAZENECA Inhaler cap strap
Nov, 2024

(1 year, 7 months from now)

US8875699

(Pediatric)

ASTRAZENECA Inhaler cap strap
May, 2025

(2 years from now)

US7587988 ASTRAZENECA Inhaler device counter
Apr, 2026

(3 years from now)

US7587988

(Pediatric)

ASTRAZENECA Inhaler device counter
Oct, 2026

(3 years from now)

US8387615 ASTRAZENECA Inhaler cap strap
Mar, 2027

(4 years from now)

US8387615

(Pediatric)

ASTRAZENECA Inhaler cap strap
Sep, 2027

(4 years from now)

US8528545 ASTRAZENECA Inhaler device that reduces the risk for miscounting a dosage
Oct, 2028

(5 years from now)

US8616196 ASTRAZENECA Inhalation device and a method for assembling said inhalation device
Apr, 2029

(6 years from now)

US8528545

(Pediatric)

ASTRAZENECA Inhaler device that reduces the risk for miscounting a dosage
Apr, 2029

(6 years from now)

US8616196

(Pediatric)

ASTRAZENECA Inhalation device and a method for assembling said inhalation device
Oct, 2029

(6 years from now)

Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE ingredient

Market Authorisation Date: 21 July, 2006

Treatment: Use for the treatment of asthma in patients 6 years of age and older; Use for reducing exacerbations of chronic obstructive pulmonary disease; Use for maintenance treatment of chronic obstructive pulmonary disease

Dosage: AEROSOL, METERED;INHALATION

How can I launch a generic of SYMBICORT before it's patent expiration?
More Information on Dosage

SYMBICORT family patents

17

United States

12

Sweden

8

Korea, Republic of

8

Japan

8

Australia

8

European Union

7

Spain

7

Austria

7

China

7

Canada

6

Germany

6

Brazil

6

New Zealand

6

Norway

6

Hong Kong

6

South Africa

6

Israel

5

Mexico

5

Argentina

5

Taiwan, Province of China

5

Denmark

4

Portugal

4

Uruguay

4

Cyprus

4

Slovenia

4

Poland

3

Malaysia

3

Russia

3

Ukraine

2

Croatia

2

Egypt

2

Saudi Arabia

2

Iceland

1

Turkey

1

Singapore

1

Colombia

1

Estonia

1

Slovakia

1

Bulgaria

1

Czech Republic

1

Finland

12. List of Tagrisso drug patents

TAGRISSO's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11524951 ASTRAZENECA 2-(2,4,5-substituted-anilino)pyrimidine compounds
Jul, 2032

(9 years from now)

US9732058 ASTRAZENECA 2-(2,4,5-substituted-anilino)pyrimidine compounds
Jul, 2032

(9 years from now)

US8946235 ASTRAZENECA 2-(2,4,5-substituted-anilino) pyrimidine compounds
Aug, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10183020 ASTRAZENECA Pharmaceutical compositions comprising AZD9291
Jan, 2035

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 18, 2027
New Indication (I) Dec 18, 2023

Drugs and Companies using OSIMERTINIB MESYLATE ingredient

Market Authorisation Date: 13 November, 2015

Treatment: Treatment of patients with metastatic epidermal growth factor receptor (egfr) t790m mutation-positive non-small cell lung cancer (nsclc), who have progressed on or after egfr tki therapy; Treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21l858r mutations; Adjuvant therapy after tumor resection in patients with non-small cell lung cancer(nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19deletions or exon 21 l858r mutations

Dosage: TABLET;ORAL

How can I launch a generic of TAGRISSO before it's patent expiration?
More Information on Dosage

TAGRISSO family patents

16

United States

9

China

7

Israel

7

European Union

6

Singapore

6

Spain

6

EA

6

Canada

6

Poland

6

Denmark

5

Portugal

5

Croatia

5

Hong Kong

5

Slovenia

5

Hungary

5

RS

4

Brazil

4

Taiwan, Province of China

4

Korea, Republic of

4

Lithuania

4

Japan

3

United Kingdom

3

Argentina

3

ME

3

Ukraine

2

Malaysia

2

Uruguay

2

Guatemala

2

Costa Rica

2

New Zealand

2

Dominican Republic

2

Philippines

2

Mexico

2

Peru

2

Nicaragua

2

Cyprus

2

Chile

2

Australia

1

San Marino

1

Colombia

1

South Africa

1

Cuba

1

Ecuador

13. List of Tudorza Pressair drug patents

TUDORZA PRESSAIR's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46417 ASTRAZENECA Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
Feb, 2025

(1 year, 10 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6681768 ASTRAZENECA Powder formulation disintegrating system and method for dry powder inhalers
Aug, 2022

(7 months ago)

US8051851 ASTRAZENECA Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler
Apr, 2027

(4 years from now)

US10085974 ASTRAZENECA Dosage and formulation
Mar, 2029

(5 years from now)

US11000517 ASTRAZENECA Dosage and formulation
Mar, 2029

(5 years from now)

Exclusivity Exclusivity Expiration
M (M) Mar 29, 2022

Drugs and Companies using ACLIDINIUM BROMIDE ingredient

Market Authorisation Date: 23 July, 2012

Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd)

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

TUDORZA PRESSAIR family patents

8

United States

8

European Union

4

Portugal

4

Russia

4

Spain

4

Korea, Republic of

4

Japan

4

Slovenia

4

Poland

4

Denmark

3

Croatia

3

Mexico

3

Peru

3

China

3

Hungary

3

RS

2

Brazil

2

New Zealand

2

Hong Kong

2

South Africa

2

Lithuania

2

Canada

2

Cyprus

2

Ukraine

2

Israel

2

Australia

2

Ecuador

1

Germany

1

Singapore

1

Malaysia

1

Uruguay

1

Colombia

1

Norway

1

Austria

1

Argentina

1

Taiwan, Province of China

1

ME

1

Chile

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in